As the Indian pharmaceutical industry gears up for its fiscal third-quarter earnings announcements, commencing with JB Chemicals & Pharmaceuticals, market analysts and investors are closely scrutinizing the sector’s ability to absorb significant headwinds while leveraging inherent strengths. The quarter ending December 2025 is widely anticipated to present a mixed financial picture, primarily characterized by margin compression stemming from the conclusion of a highly lucrative revenue stream and persistent pricing pressures in key international markets. However, robust performance in the domestic market and strategic expansion in other global territories are expected to provide a crucial offset, underscoring the sector’s evolving dynamics.
A central narrative dominating the Q3 outlook is the substantial impact of the patent expiry for lenalidomide, a blood cancer drug widely known by its brand name Revlimid. This blockbuster medication, which has generated over $100 billion in global sales since its launch, proved to be a significant revenue and profitability driver for several Indian pharmaceutical majors. Companies such as Dr. Reddy’s Laboratories, Cipla, Zydus Lifesciences, Sun Pharma, and Aurobindo Pharma had entered into intricate patent settlements with the innovator, Mylan (now part of Viatris), allowing them to sell generic versions in limited quantities in the U.S. market from 2022 until the patent’s full expiration in January 2026. This phased entry allowed Indian players to capture substantial market share and realize elevated margins on their generic Revlimid (gRevlimid) sales.
However, as these firms conclude offloading their remaining quotas throughout the current fiscal year, the third quarter is projected to witness a sharp erosion in gRevlimid revenues. Analysts at BNP Paribas, for instance, have specifically pointed to expected EBITDA margin declines for Dr. Reddy’s, Cipla, and Zydus Lifesciences, attributing this directly to the sharp depreciation in gRevlimid prices as companies liquidate their residual inventories ahead of the full patent expiry. This aggressive price competition for the diminishing market share of gRevlimid reflects a common phenomenon in the generics landscape as patent cliffs loom.
Beyond the Revlimid-related headwinds, the broader U.S. generics market continues to pose challenges. Persistent price competition across a range of generic drugs remains a structural impediment to revenue growth and margin expansion for Indian pharmaceutical companies heavily reliant on the American market. This competitive intensity is exacerbated by consolidation among U.S. drug wholesalers and pharmacy chains, which wield significant purchasing power, further pressuring manufacturers’ profitability. Consequently, Kotak Securities analysts forecast a 4% quarter-on-quarter (QoQ) decline in overall U.S. sales for their coverage universe, largely factoring in sequentially lower gRevlimid contributions from major players like Dr. Reddy’s, Cipla, Sun Pharma, and Aurobindo Pharma.
Operational cost pressures are also expected to weigh on the sector’s profitability. Increased investments in research and development (R&D) are a strategic necessity for Indian pharmaceutical companies aiming to transition from a pure-play generics model to developing complex generics, biosimilars, and even novel drugs. While crucial for long-term growth, these upfront R&D expenditures impact current-quarter margins. Furthermore, higher selling, general, and administrative (SG&A) costs, including the addition of new medical representatives to bolster sales efforts in the burgeoning domestic market, will contribute to margin contraction. HDFC Securities, in its analysis, highlighted these factors as likely contributors to the overall margin impact in Q3. Collectively, these pressures have led Kotak Securities analysts to anticipate an average 150 basis points year-on-year (YoY) decline in the sector’s EBITDA margins.
Despite these significant pressures, the resilience of the Indian domestic pharmaceutical market (IPM) is poised to act as a crucial counterweight. The IPM has consistently demonstrated robust growth, driven by an expanding middle class, increasing healthcare expenditure, and a growing burden of chronic diseases. For the October-November 2025 period, the IPM recorded a healthy growth rate of 10.1%. This expansion was notably propelled by the chronic therapy segment, which surged by 15%, reflecting demographic shifts and lifestyle-related health issues. The acute segment also registered a respectable 7% growth.
Indian pharmaceutical companies with strong domestic footprints and specialized portfolios are well-positioned to capitalize on this trend. HDFC Securities projects an 11% YoY growth in the India business for its coverage universe, attributing this to robust traction in specialty portfolios (e.g., Sun Pharma, Zydus Lifesciences) and the chronic segment (e.g., Sun Pharma, Torrent Pharmaceuticals). Conversely, muted growth in anti-infectives could slightly temper the overall domestic momentum for some companies like Alkem Laboratories and Mankind Pharma. This domestic strength highlights the strategic importance of balancing international ambitions with a robust presence in the home market, offering a stable revenue base amidst global volatility.
Beyond the immediate U.S. challenges and the domestic market’s strength, other international markets and specific product successes are contributing to ex-U.S. growth. Excluding gRevlimid, U.S. generic sales are still expected to see a modest 2% QoQ growth, driven by volume increases in existing products and the sustained benefit from new product launches in previous quarters for certain firms. For example, Lupin is anticipated to continue its strong performance with Tolvaptan, a kidney function drug, and benefit from a full quarter of sales for Glucagon, used to treat hypoglycemia. Sun Pharma is also expected to achieve sequential growth, buoyed by its innovative medicines portfolio, including products like Leqselvi, Cequa, Winlevi, and Odomzo. Similarly, Cipla may see higher QoQ sales for its cancer drug, Abraxane, signaling a broader strategy of diversifying into more complex and specialty products that command better pricing and margins than traditional generics.
The Contract Research and Development (CR&D) segment within the broader pharmaceutical ecosystem is also showing signs of steady progress. Companies specializing in CR&D are projected to record approximately 6% YoY sales growth, with their margins largely sustained as capacities mature and operational efficiencies improve. This segment is critical for supporting the innovation pipeline of both Indian and global pharmaceutical firms, indicating a deeper integration into the global drug development value chain.
Looking ahead, the Indian pharmaceutical sector is navigating a pivotal transition. The era of super-normal profits from easy-to-manufacture generics, particularly those benefiting from patent settlements for blockbuster drugs like Revlimid, is gradually receding. The industry is being compelled to innovate, differentiate, and diversify. This involves a strategic pivot towards complex generics, biosimilars, specialty pharmaceuticals, and even novel drug discovery, albeit with higher R&D investments and longer gestation periods. Companies are also intensifying their focus on emerging markets beyond the U.S. and Europe, where healthcare needs are growing, and competition might be less intense.
The economic impact of these shifts is multifaceted. While the immediate margin pressures might temper export revenue growth, the underlying strength of the domestic market and strategic investments in R&D are critical for long-term sustainability. A robust pharmaceutical sector contributes significantly to India’s foreign exchange earnings, generates high-skill employment, and strengthens the country’s position as a global healthcare hub. The current quarter’s earnings will provide crucial insights into how effectively Indian pharma giants are executing these strategic transitions, balancing the immediate imperative of profitability with the long-term vision of sustainable growth and innovation in a rapidly evolving global landscape. The upcoming earnings season will thus serve as a barometer for the sector’s adaptability and its future trajectory in a post-Revlimid world.
